|
US7981420B2
(en)
|
2000-12-22 |
2011-07-19 |
Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. |
Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
|
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
EP2033971A1
(de)
*
|
2007-09-06 |
2009-03-11 |
Abbott GmbH & Co. KG |
Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
|
KR101658247B1
(ko)
|
2008-01-03 |
2016-09-22 |
더 스크립스 리서치 인스티튜트 |
모듈 인식 도메인을 통한 항체 표적화
|
|
US8962803B2
(en)
*
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
NO2344540T3
(https=)
|
2008-10-02 |
2018-04-28 |
|
|
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
|
US8133979B2
(en)
*
|
2008-12-16 |
2012-03-13 |
Hoffmann-La Roche Inc. |
Antibodies against human angiopoietin 2
|
|
CA2756244A1
(en)
*
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
|
SG175077A1
(en)
|
2009-04-07 |
2011-11-28 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
PE20120540A1
(es)
*
|
2009-05-27 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos triespecificos o tetraespecificos
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
EP2478013B1
(en)
|
2009-09-16 |
2018-10-24 |
F.Hoffmann-La Roche Ag |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
US20110172398A1
(en)
*
|
2009-10-02 |
2011-07-14 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules for anti-angiogenesis therapy
|
|
AU2010306774A1
(en)
*
|
2009-10-14 |
2012-05-03 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
|
|
MX2012006560A
(es)
*
|
2009-12-08 |
2012-10-05 |
Abbott Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
CA2785907A1
(en)
*
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Ron binding constructs and methods of use thereof
|
|
AR080794A1
(es)
|
2010-03-26 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
|
|
TW201138821A
(en)
*
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
UY33492A
(es)
*
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
RU2012157167A
(ru)
|
2010-07-12 |
2014-08-20 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Полифункциональные антительные конъюгаты
|
|
WO2012009705A1
(en)
*
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
|
CA2805618A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
EP3252072A3
(en)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
CN102372778B
(zh)
*
|
2010-08-19 |
2015-06-17 |
上海抗体药物国家工程研究中心有限公司 |
抗人vegf和opn双特异性抗体、其制备方法及用途
|
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
AR085404A1
(es)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
Proteinas de union a antigeno
|
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
|
EP2686334B2
(en)
|
2011-03-16 |
2020-07-01 |
F.Hoffmann-La Roche Ag |
Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
|
|
IN2013MN01438A
(https=)
|
2011-03-17 |
2015-06-12 |
Univ Ramot |
|
|
US9527925B2
(en)
*
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
|
US20130078247A1
(en)
*
|
2011-04-01 |
2013-03-28 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to dii4 and ang2
|
|
EP2714738B1
(en)
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
CA2850572A1
(en)
*
|
2011-10-20 |
2013-04-25 |
Esbatech, A Novartis Company Llc |
Stable multiple antigen-binding antibody
|
|
ES2651521T3
(es)
|
2011-12-01 |
2018-01-26 |
Innovent Biologics, Inc. |
Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
|
|
CN102936277B
(zh)
*
|
2011-12-29 |
2014-10-01 |
北京五康新兴科技有限公司 |
人血管内皮生长因子抗原表位及其表位疫苗
|
|
EP3369746A1
(en)
|
2012-01-27 |
2018-09-05 |
AbbVie Deutschland GmbH & Co KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
CA2861124A1
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
|
MX360352B
(es)
|
2012-02-15 |
2018-10-30 |
Hoffmann La Roche |
Cromatografia de afinidad basada en receptores fc.
|
|
WO2013134414A1
(en)
*
|
2012-03-06 |
2013-09-12 |
Galaxy Biotech, Llc |
Bispecific antibodies with an fgf2 binding domain
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
JP6509724B2
(ja)
|
2012-04-20 |
2019-05-08 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Ｃｄ３結合ポリペプチド
|
|
TW201823460A
(zh)
|
2012-05-29 |
2018-07-01 |
美商再生元醫藥公司 |
生產細胞株增強子
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
|
SG11201408538PA
(en)
*
|
2012-07-13 |
2015-02-27 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
ES2627482T3
(es)
*
|
2012-07-13 |
2017-07-28 |
F. Hoffmann-La Roche Ag |
Procedimiento para la detección de una proteína de unión multiespecífica
|
|
JP6422022B2
(ja)
*
|
2012-08-31 |
2018-11-14 |
国立大学法人大阪大学 |
Ｖｅｇｆ及び／又はアンギオポエチン−２の特異的エピトープを含むｄｎａワクチン
|
|
JP2015532272A
(ja)
*
|
2012-09-28 |
2015-11-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
|
|
KR20150060686A
(ko)
*
|
2012-09-28 |
2015-06-03 |
베링거 인겔하임 인터내셔날 게엠베하 |
이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물
|
|
CN104755489B
(zh)
|
2012-10-30 |
2019-01-15 |
弗·哈夫曼-拉罗切有限公司 |
使用双级切线流超滤纯化多肽
|
|
TW202037609A
(zh)
|
2012-11-01 |
2020-10-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
|
US10150800B2
(en)
|
2013-03-15 |
2018-12-11 |
Zyngenia, Inc. |
EGFR-binding modular recognition domains
|
|
UA118029C2
(uk)
*
|
2013-04-29 |
2018-11-12 |
Ф. Хоффманн-Ля Рош Аг |
Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
|
|
WO2014177459A2
(en)
*
|
2013-04-29 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
KR102131371B1
(ko)
|
2013-07-02 |
2020-07-08 |
삼성전자주식회사 |
Ang-2 특이적 항체 및 그의 용도
|
|
ES2742855T3
(es)
*
|
2013-07-09 |
2020-02-17 |
Ablbio |
Nueva proteína de objetivo doble que se une específicamente a DLL4 y CEGF, y uso de la misma
|
|
KR102060187B1
(ko)
|
2013-07-19 |
2019-12-27 |
삼성전자주식회사 |
Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
|
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
CN103604923B
(zh)
*
|
2013-10-22 |
2015-05-13 |
卫生部北京医院 |
检测抗甲状腺过氧化物酶和甲状腺球蛋白的天然双特异性抗体的试剂盒
|
|
KR102178323B1
(ko)
*
|
2013-11-29 |
2020-11-13 |
삼성전자주식회사 |
항 c-Met/항 Ang2 이중 특이 항체
|
|
JP6568521B2
(ja)
*
|
2013-12-13 |
2019-08-28 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多価多重特異性分子の生物学的活性を決定するためのｓｐｒベースの架橋アッセイ
|
|
CN105611944A
(zh)
*
|
2013-12-20 |
2016-05-25 |
豪夫迈·罗氏有限公司 |
抗ang2抗体和cd40激动剂的组合疗法
|
|
MX380658B
(es)
|
2014-01-15 |
2025-03-11 |
Hoffmann La Roche |
Variantes de region fc con union mejorada de la proteina a.
|
|
AR100271A1
(es)
*
|
2014-05-19 |
2016-09-21 |
Lilly Co Eli |
Compuestos de vegfr2 / ang2
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
CA2953698A1
(en)
*
|
2014-06-28 |
2015-12-30 |
Kodiak Sciences Inc. |
Dual pdgf/vegf antagonists
|
|
EP3174897B1
(en)
*
|
2014-07-29 |
2020-02-12 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
KR102390359B1
(ko)
|
2014-09-29 |
2022-04-22 |
삼성전자주식회사 |
폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
|
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
DK3215528T3
(da)
*
|
2014-11-06 |
2019-10-07 |
Hoffmann La Roche |
Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
|
|
CA2960569A1
(en)
*
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-Laroche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
BR112017009764A2
(pt)
|
2014-11-10 |
2018-02-20 |
Hoffmann La Roche |
anticorpos biespecíficos e métodos de uso em oftalmologia
|
|
JP6787888B2
(ja)
|
2014-11-10 |
2020-11-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗ｉｌ−１ベータ抗体及び使用方法
|
|
JP2017534644A
(ja)
*
|
2014-11-10 |
2017-11-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗ａｎｇ２抗体及び使用方法
|
|
RU2017120361A
(ru)
|
2014-11-10 |
2018-12-13 |
Ф.Хоффманн-Ля Рош Аг |
Антитела к pdgf-b и способы их применения
|
|
US20160144025A1
(en)
*
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
AR103477A1
(es)
|
2015-01-28 |
2017-05-10 |
Lilly Co Eli |
Compuestos de vegfa / ang2
|
|
CN104818295A
(zh)
*
|
2015-02-03 |
2015-08-05 |
武汉友芝友生物制药有限公司 |
制备和筛选表达双特异性抗体细胞株的方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
CA2992660A1
(en)
*
|
2015-07-29 |
2017-02-02 |
Allergan, Inc. |
Heavy chain only antibodies to ang-2
|
|
KR20180068982A
(ko)
*
|
2015-09-14 |
2018-06-22 |
갤럭시 바이오테크, 엘엘씨 |
혈관신생 인자에 대한 매우 강력한 모노클로날 항체
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
CN108290958B
(zh)
*
|
2015-10-02 |
2021-12-28 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
EP3150637A1
(en)
*
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
CN108699162A
(zh)
*
|
2015-11-30 |
2018-10-23 |
皮里斯澳大利亚有限公司 |
新型抗血管生成融合多肽
|
|
KR20250057128A
(ko)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
KR102293753B1
(ko)
|
2016-01-06 |
2021-08-24 |
오더-메이드 메디컬 리서치 인코포레이티드 |
Vegf 와 nrp1 의 결합을 저해하는 항체
|
|
US11007259B2
(en)
|
2016-01-06 |
2021-05-18 |
Order-Made Medical Research Inc. |
High-affinity anti-VEGF antibody
|
|
US10894823B2
(en)
*
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
|
WO2018007314A1
(en)
*
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
|
BR112019001206A2
(pt)
|
2016-07-20 |
2019-06-25 |
Aerpio Therapeutics Inc |
anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
|
|
US10836819B2
(en)
|
2016-08-23 |
2020-11-17 |
Medimmune Limited |
Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
|
|
WO2018114728A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
|
|
WO2018122053A1
(en)
|
2016-12-29 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
Anti-angiopoietin-2 antibody formulation
|
|
MA49279A
(fr)
|
2017-03-22 |
2020-02-05 |
Hoffmann La Roche |
Compositions d'anticorps optimisées pour le traitement de troubles oculaires
|
|
CN108659112B
(zh)
*
|
2017-03-30 |
2021-01-26 |
上海市同济医院 |
一种非对称双特异性抗体
|
|
KR20240017409A
(ko)
*
|
2017-04-13 |
2024-02-07 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
US11198726B2
(en)
|
2017-06-02 |
2021-12-14 |
Boerhinger Ingelheim International Gmbh |
Anti-cancer combination therapy
|
|
SG11202006712XA
(en)
|
2018-02-06 |
2020-08-28 |
Hoffmann La Roche |
Treatment of ophthalmologic diseases
|
|
EP3758737A4
(en)
|
2018-03-02 |
2022-10-12 |
Kodiak Sciences Inc. |
IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
|
|
CA3095373A1
(en)
*
|
2018-04-13 |
2019-10-17 |
Affimed Gmbh |
Nk cell engaging antibody fusion constructs
|
|
US12048745B2
(en)
|
2018-05-01 |
2024-07-30 |
Augusta University Research Institute, Inc. |
Methods for detecting and reversing immune therapy resistance
|
|
EP3805757A4
(en)
*
|
2018-06-04 |
2022-03-23 |
Chugai Seiyaku Kabushiki Kaisha |
Method for detecting complex
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
US10597453B2
(en)
*
|
2018-06-29 |
2020-03-24 |
Gensun Biopharma, Inc. |
Antitumor immune checkpoint regulator antagonists
|
|
US11377488B2
(en)
*
|
2018-07-03 |
2022-07-05 |
Catalent Pharma Solutions, Llc |
Multifunctional protein molecules comprising decorin and use thereof
|
|
WO2020025792A1
(en)
*
|
2018-08-03 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Antibody constructs for cldn18.2 and cd3
|
|
EP3836959A4
(en)
*
|
2018-08-17 |
2022-05-11 |
Trican Biotechnology Co., Ltd |
ANTI-ANGIOGENESIS FUSION PROTEIN AND USES ITS
|
|
US11066476B2
(en)
|
2018-09-14 |
2021-07-20 |
Shanghai tongji hospital |
Asymmetric bispecific antibody
|
|
WO2020068653A1
(en)
|
2018-09-24 |
2020-04-02 |
Aerpio Pharmaceuticals, Inc. |
MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
|
|
MY195550A
(en)
|
2018-10-29 |
2023-01-31 |
Hoffmann La Roche |
Antibody Formulation
|
|
US20220185875A1
(en)
*
|
2019-03-18 |
2022-06-16 |
Jiangsu Hengrui Medicine Co., Ltd. |
Bispecific antibody specifically bound to vegf and ang2
|
|
EP3986924A1
(en)
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
AU2020294879A1
(en)
|
2019-06-19 |
2021-12-16 |
F. Hoffmann-La Roche Ag |
Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
TWI785360B
(zh)
*
|
2019-08-06 |
2022-12-01 |
美商建南德克公司 |
眼科疾病之個人化治療
|
|
CN115947846A
(zh)
|
2019-09-12 |
2023-04-11 |
普米斯生物技术(珠海)有限公司 |
一种抗pd-l1纳米抗体及其衍生物和用途
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
JP7638989B2
(ja)
*
|
2019-11-21 |
2025-03-04 |
ユニティ バイオテクノロジー インコーポレイテッド |
Ｔｉｅ－２に対する抗体および使用方法
|
|
AU2021242249A1
(en)
|
2020-03-24 |
2022-08-18 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
|
WO2022010273A1
(ko)
|
2020-07-07 |
2022-01-13 |
주식회사 카나프테라퓨틱스 |
보체 경로 억제제를 포함하는 융합단백질 및 이의 용도
|
|
US20230181471A1
(en)
*
|
2020-07-09 |
2023-06-15 |
Hoffmann-La Roche Inc. |
Concentrated compositions of proteins, their preparation and use thereof
|
|
TW202216777A
(zh)
*
|
2020-07-10 |
2022-05-01 |
美商生質分子控股有限責任公司 |
四面體抗體
|
|
CN114106190B
(zh)
*
|
2020-08-31 |
2025-04-08 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
|
EP4208201A1
(en)
*
|
2020-09-04 |
2023-07-12 |
F. Hoffmann-La Roche AG |
Antibody that binds to vegf-a and ang2 and methods of use
|
|
WO2022057888A1
(zh)
*
|
2020-09-17 |
2022-03-24 |
江苏恒瑞医药股份有限公司 |
特异性结合vegf和ang-2的双特异性抗原结合分子
|
|
EP4232474A1
(en)
*
|
2020-10-21 |
2023-08-30 |
Boehringer Ingelheim International GmbH |
Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
|
|
CN114957465A
(zh)
*
|
2021-02-25 |
2022-08-30 |
武汉友芝友生物制药股份有限公司 |
针对vegf的抗体及其制备方法和应用
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
WO2022256820A1
(en)
*
|
2021-06-03 |
2022-12-08 |
Gensun Biopharma Inc. |
Multispecific antagonists
|
|
IL309035A
(en)
*
|
2021-06-04 |
2024-02-01 |
Innovent Biologics Suzhou Co Ltd |
A bispecific binding molecule that binds to VEGF and ANG2 and its use
|
|
CN116265487B
(zh)
*
|
2021-12-16 |
2025-01-10 |
三优生物医药(上海)有限公司 |
抗ang2-vegf双特异性抗体及其用途
|
|
KR20230105972A
(ko)
|
2022-01-05 |
2023-07-12 |
주식회사 카나프테라퓨틱스 |
혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
|
|
CN116925234B
(zh)
*
|
2022-04-02 |
2024-05-31 |
合肥星眸生物科技有限公司 |
一种编码抗vegf-a和ang-2双特异性抗体的aav载体
|
|
US20250290925A1
(en)
*
|
2022-05-04 |
2025-09-18 |
Kephera Diagnostics, Llc |
Method for detecting lyme disease
|
|
EP4596579A1
(en)
*
|
2022-09-28 |
2025-08-06 |
Kexing Biopharm Co., Ltd. |
Antibody or antigen-binding fragment capable of identifying ang-2, and bispecific antibody for simultaneously identifying vegf and ang-2
|
|
WO2024076993A2
(en)
*
|
2022-10-03 |
2024-04-11 |
Therini Bio, Inc. |
Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use
|
|
WO2025178426A1
(ko)
*
|
2024-02-23 |
2025-08-28 |
주식회사 알토스바이오로직스 |
신규한 항-ang-2 항체 및 이의 용도
|
|
WO2025219504A1
(en)
|
2024-04-19 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
|
WO2025252203A1
(zh)
*
|
2024-06-06 |
2025-12-11 |
江苏恒瑞医药股份有限公司 |
抗Nectin-4抗体药物偶联物治疗肿瘤的用途
|